The SARS-CoV S glycoprotein
- PMID:15526150
- PMCID: PMC7079772
- DOI: 10.1007/s00018-004-4257-y
The SARS-CoV S glycoprotein
Abstract
The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. Recent rapid advances in our knowledge of the structure and function of this protein have lead to the development of a number of candidate vaccine immunogens and SARS-CoV entry inhibitors.
Similar articles
- Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies.He Y.He Y.Adv Exp Med Biol. 2006;581:539-42. doi: 10.1007/978-0-387-33012-9_98.Adv Exp Med Biol. 2006.PMID:17037594Free PMC article.No abstract available.
- Genetic analysis of the SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression and cell-to-cell fusion.Petit CM, Melancon JM, Chouljenko VN, Colgrove R, Farzan M, Knipe DM, Kousoulas KG.Petit CM, et al.Virology. 2005 Oct 25;341(2):215-30. doi: 10.1016/j.virol.2005.06.046. Epub 2005 Aug 15.Virology. 2005.PMID:16099010Free PMC article.
- Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide.Madu IG, Roth SL, Belouzard S, Whittaker GR.Madu IG, et al.J Virol. 2009 Aug;83(15):7411-21. doi: 10.1128/JVI.00079-09. Epub 2009 May 13.J Virol. 2009.PMID:19439480Free PMC article.
- Insights from the association of SARS-CoV S-protein with its receptor, ACE2.Li W, Choe H, Farzan M.Li W, et al.Adv Exp Med Biol. 2006;581:209-18. doi: 10.1007/978-0-387-33012-9_36.Adv Exp Med Biol. 2006.PMID:17037532Free PMC article.Review.No abstract available.
- The spike protein of SARS-CoV--a target for vaccine and therapeutic development.Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S.Du L, et al.Nat Rev Microbiol. 2009 Mar;7(3):226-36. doi: 10.1038/nrmicro2090. Epub 2009 Feb 9.Nat Rev Microbiol. 2009.PMID:19198616Free PMC article.Review.
Cited by
- Computational characterization and design of SARS coronavirus receptor recognition and antibody neutralization.Zhang Y, Zheng N, Zhong Y.Zhang Y, et al.Comput Biol Chem. 2007 Apr;31(2):129-33. doi: 10.1016/j.compbiolchem.2007.02.005. Epub 2007 Feb 17.Comput Biol Chem. 2007.PMID:17374510Free PMC article.
- Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses.Liniger M, Zuniga A, Tamin A, Azzouz-Morin TN, Knuchel M, Marty RR, Wiegand M, Weibel S, Kelvin D, Rota PA, Naim HY.Liniger M, et al.Vaccine. 2008 Apr 16;26(17):2164-74. doi: 10.1016/j.vaccine.2008.01.057. Epub 2008 Feb 22.Vaccine. 2008.PMID:18346823Free PMC article.
- Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody.Prabakaran P, Gan J, Feng Y, Zhu Z, Choudhry V, Xiao X, Ji X, Dimitrov DS.Prabakaran P, et al.J Biol Chem. 2006 Jun 9;281(23):15829-36. doi: 10.1074/jbc.M600697200. Epub 2006 Apr 5.J Biol Chem. 2006.PMID:16597622Free PMC article.
- A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice.Zhou Z, Post P, Chubet R, Holtz K, McPherson C, Petric M, Cox M.Zhou Z, et al.Vaccine. 2006 Apr 24;24(17):3624-31. doi: 10.1016/j.vaccine.2006.01.059. Epub 2006 Feb 9.Vaccine. 2006.PMID:16497416Free PMC article.
- Why are HIV-1 fusion inhibitors not effective against SARS-CoV? Biophysical evaluation of molecular interactions.Veiga S, Yuan Y, Li X, Santos NC, Liu G, Castanho MA.Veiga S, et al.Biochim Biophys Acta. 2006 Jan;1760(1):55-61. doi: 10.1016/j.bbagen.2005.10.001. Epub 2005 Oct 28.Biochim Biophys Acta. 2006.PMID:16290276Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Miscellaneous